HIGHTIDE-B (02511) announced its annual results for the period ending December 31, 2025. The group recorded other income of 19.007 million yuan, a decrease of 72.04% compared to the previous year. The loss attributable to company owners was 245 million yuan, narrowing by 35.84% year-on-year. The loss per share was 0.51 yuan. The company's research and development team possesses extensive expertise, deep understanding, and broad development experience in CKM-related diseases. The company's drug discovery and clinical activities include coordinating all clinical development activities, designing key aspects of clinical studies, and designing and coordinating the selection process for qualified contract research organizations to assist in the appointment of clinical sites and coordination after the commencement of studies. Additionally, the team oversees clinical research and manages extensive regulatory outreach and coordination efforts in China and other jurisdictions. The R&D team is led by a group of world-class scientists with many years of experience in drug development.